ALK and non-small cell lung carcinoma: Alectinib was developed to be more selective than crizotinib and active against known crizotinib-resistant ALK mutations, and it has recently been approved by FDA as second-line treatment of advanced ALK+ NSCLC who failed crizotinib [20].